NCT01657526View on ClinicalTrials.gov

Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 8, 2012

Primary Completion Date

November 25, 2013

Study Completion Date

November 25, 2013

Conditions
Respiratory Disorders
Interventions
BIOLOGICAL

GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)

Administered intramuscularly (IM) in the deltoid region of non-dominant arm

BIOLOGICAL

GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)

2 doses administered IM in the deltoid region of non-dominant arm

BIOLOGICAL

Saline placebo

2 doses administered IM in the deltoid region of non-dominant arm

Trial Locations (1)

5000

GSK Investigational Site, Adelaide

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01657526 - Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine | Biotech Hunter | Biotech Hunter